The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats.
metabolic dysfunction
microbiome
obesity
pharmacomicrobiomics
psychopharmacology
psycho‐pharmacomicrobiomics
schizophrenia
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
revised:
06
06
2024
received:
03
03
2024
accepted:
10
06
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
Antipsychotics such as olanzapine are associated with significant metabolic dysfunction, attributed to gut microbiome dysbiosis. A recent notion that most psychotropics are detrimental to the gut microbiome has arisen from consistent findings of metabolic adverse effects. However, unlike olanzapine, the metabolic effects of lurasidone are conflicting. Thus, this study investigates the contrasting effects of olanzapine and lurasidone on the gut microbiome to explore the hypothesis of 'gut neutrality' for lurasidone exposure. Using Sprague-Dawley rats, the effects of olanzapine and lurasidone on the gut microbiome were explored. Faecal and blood samples were collected weekly over a 21-day period to analyse changes to the gut microbiome and related metabolic markers. Lurasidone triggered no significant weight gain or metabolic alterations, instead positively modulating the gut microbiome through increases in mean operational taxonomical units (OTUs) and alpha diversity. This novel finding suggests an underlying mechanism for lurasidone's metabolic inertia. In contrast, olanzapine triggered a statistically significant decrease in mean OTUs, substantial compositional variation and a depletion in short-chain fatty acid abundance. Microbiome depletion correlated with metabolic dysfunction, producing a 30% increase in weight gain, increased pro-inflammatory cytokine expression, and increased blood glycaemic and triglyceride levels. Our results challenge the notion that all antipsychotics disrupt the gut microbiome similarly and highlights the potential benefits of gut-neutral antipsychotics, such as lurasidone, in managing metabolic side effects. Further research is warranted to validate these findings in humans to guide personalised pharmacological treatment regimens for schizophrenia.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Antipsychotics such as olanzapine are associated with significant metabolic dysfunction, attributed to gut microbiome dysbiosis. A recent notion that most psychotropics are detrimental to the gut microbiome has arisen from consistent findings of metabolic adverse effects. However, unlike olanzapine, the metabolic effects of lurasidone are conflicting. Thus, this study investigates the contrasting effects of olanzapine and lurasidone on the gut microbiome to explore the hypothesis of 'gut neutrality' for lurasidone exposure.
EXPERIMENTAL APPROACH
METHODS
Using Sprague-Dawley rats, the effects of olanzapine and lurasidone on the gut microbiome were explored. Faecal and blood samples were collected weekly over a 21-day period to analyse changes to the gut microbiome and related metabolic markers.
KEY RESULTS
RESULTS
Lurasidone triggered no significant weight gain or metabolic alterations, instead positively modulating the gut microbiome through increases in mean operational taxonomical units (OTUs) and alpha diversity. This novel finding suggests an underlying mechanism for lurasidone's metabolic inertia. In contrast, olanzapine triggered a statistically significant decrease in mean OTUs, substantial compositional variation and a depletion in short-chain fatty acid abundance. Microbiome depletion correlated with metabolic dysfunction, producing a 30% increase in weight gain, increased pro-inflammatory cytokine expression, and increased blood glycaemic and triglyceride levels.
CONCLUSION AND IMPLICATIONS
CONCLUSIONS
Our results challenge the notion that all antipsychotics disrupt the gut microbiome similarly and highlights the potential benefits of gut-neutral antipsychotics, such as lurasidone, in managing metabolic side effects. Further research is warranted to validate these findings in humans to guide personalised pharmacological treatment regimens for schizophrenia.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hospital Research Foundation
ID : 2022-CF-EMCR-004-25314
Informations de copyright
© 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Ågren, R. (2021). Worldwide antipsychotic drug search intensities: Pharmacoepidemological estimations based on Google trends data. Scientific Reports, 11(1), 13136. https://doi.org/10.1038/s41598-021-92204-0
Abuqwider, J., Di Porzio, A., Barrella, V., Gatto, C., Sequino, G., De Filippis, F., Crescenzo, R., Spagnuolo, M. S., Cigliano, L., Mauriello, G., Iossa, S., Mazzoli, A. (2023). Limosilactobacillus reuteri DSM 17938 reverses gut metabolic dysfunction induced by Western diet in adult rats. Frontiers in Nutrition, 10, 1236417. https://doi.org/10.3389/fnut.2023.1236417
Ait Chait, Y., Mottawea, W., Tompkins, T. A., & Hammami, R. (2021). Nutritional and therapeutic approaches for protecting human gut microbiota from psychotropic treatments. Progress in Neuro‐Psychopharmacology and Biological Psychiatry, 108, 110182. https://doi.org/10.1016/j.pnpbp.2020.110182
Ait Chait, Y., Mottawea, W., Tompkins, T. A., & Hammami, R. (2023). Evidence of the Dysbiotic effect of Psychotropics on gut microbiota and capacity of probiotics to alleviate related Dysbiosis in a model of the human colon. International Journal of Molecular Sciences, 24(8), 7326. https://doi.org/10.3390/ijms24087326
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., Abbracchio, M. P., Abraham, G., Agoulnik, A., Alexander, W., Al‐hosaini, K., Bäck, M., Baker, J. G., Barnes, N. M., … Ye, R. D. (2023). The concise guide to PHARMACOLOGY 2023/24: G protein‐coupled receptors. British Journal of Pharmacology, 180(S2), S23–S144. https://doi.org/10.1111/bph.16177
Aoun, A., Darwish, F., & Hamod, N. (2020). The influence of the gut microbiome on obesity in adults and the role of probiotics, prebiotics, and Synbiotics for weight loss. Preventive Nutrition and Food Science, 25(2), 113–123. https://doi.org/10.3746/pnf.2020.25.2.113
Appleton, J. (2018). The gut‐brain Axis: Influence of microbiota on mood and mental health. Integrative Medicine: a Clinician's Journal, 17(4), 28.
Australian Institute of Health and Welfare (AIHW) 2024, Medicare Benefits Scheme funded services: Monthly data. (n.d.). https://www.aihw.gov.au/reports/medicare/mbs-funded-services-data
Bahr, S. M., Weidemann, B. J., Castro, A. N., Walsh, J. W., deLeon, O., Burnett, C. M. L., Pearson, N. A., Murry, D. J., Grobe, J. L., & Kirby, J. R. (2015). Risperidone‐induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. eBioMedicine, 2(11), 1725–1734. https://doi.org/10.1016/j.ebiom.2015.10.018
Batt, C. A., & Tortorello, M. L. (Eds.). (2014). Encyclopedia of food microbiology (2nd ed.). AP, Academic Press/Elsevier.
Bear, T., Dalziel, J., Coad, J., Roy, N., Butts, C., & Gopal, P. (2021). The microbiome‐gut‐brain Axis and resilience to developing anxiety or depression under stress. Microorganisms, 9(4), Article 4. https://doi.org/10.3390/microorganisms9040723
Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018). Vagus nerve as modulator of the brain–gut Axis in psychiatric and inflammatory disorders. Frontiers in Psychiatry, 9, 44. https://doi.org/10.3389/fpsyt.2018.00044
Burnet, P. W. (2015). S.20.02 prebiotics and anxiety: Translational studies toward new therapeutic strategies. European Neuropsychopharmacology, 25, S141. https://doi.org/10.1016/S0924-977X(15)30097-3
Clapp, M., Aurora, N., Herrera, L., Bhatia, M., Wilen, E., & Wakefield, S. (2017). Gut Microbiota's effect on mental health: The gut‐brain Axis. Clinics and Practice, 7(4), 987. https://doi.org/10.4081/cp.2017.987
Cross, C., Davies, M., Bateman, E., Crame, E., Joyce, P., Wignall, A., Ariaee, A., Gladman, M. A., Wardill, H., & Bowen, J. (2024). Fibre‐rich diet attenuates chemotherapy‐related neuroinflammation in mice. Brain, Behavior, and Immunity, 115, 13–25. https://doi.org/10.1016/j.bbi.2023.09.018
Curtis, M. J., Alexander, S. P. H., Cirino, G., George, C. H., Kendall, D. A., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Patel, H. H., Sobey, C. G., Stanford, S. C., Stanley, P., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., & Ahluwalia, A. (2022). Planning experiments: Updated guidance on experimental design and analysis and their reporting III. British Journal of Pharmacology, 179(15), 3907–3913. https://doi.org/10.1111/bph.15868
Cussotto, S., Clarke, G., Dinan, T. G., & Cryan, J. F. (2019). Psychotropics and the microbiome: A chamber of secrets …. Psychopharmacology, 236(5), 1411–1432. https://doi.org/10.1007/s00213-019-5185-8
Cussotto, S., Walsh, J., Golubeva, A. V., Zhdanov, A. V., Strain, C. R., Fouhy, F., Stanton, C., Dinan, T. G., Hyland, N. P., Clarke, G., Cryan, J. F., & Griffin, B. T. (2021). The gut microbiome influences the bioavailability of olanzapine in rats. eBioMedicine, 66, 103307. https://doi.org/10.1016/j.ebiom.2021.103307
Davey, K. J., Cotter, P. D., O'Sullivan, O., Crispie, F., Dinan, T. G., Cryan, J. F., & O'Mahony, S. M. (2013). Antipsychotics and the gut microbiome: Olanzapine‐induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Translational Psychiatry, 3(10), e309. https://doi.org/10.1038/tp.2013.83
Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & De Silva, V. (2017). Antipsychotic‐associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatric Disease and Treatment, 13, 2231–2241. https://doi.org/10.2147/NDT.S113099
Forsgård, R. A., Marrachelli, V. G., Korpela, K., Frias, R., Collado, M. C., Korpela, R., Monleon, D., Spillmann, T., & Österlund, P. (2017). Chemotherapy‐induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague–Dawley rats. Cancer Chemotherapy and Pharmacology, 80(2), 317–332. https://doi.org/10.1007/s00280-017-3364-z
Greger, J., Aladeen, T., Lewandowski, E., Wojcik, R., Westphal, E., Rainka, M., & Capote, H. (2021). Comparison of the metabolic characteristics of newer second generation antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone with olanzapine as a comparator. Journal of Clinical Psychopharmacology, 41(1), 5–12. https://doi.org/10.1097/JCP.0000000000001318
Hao, S., Zhou, Y., Zhang, X., & Jiang, H. (2023). Gut microbiome profiles may be related to atypical antipsychotic associated overweight in Asian children with psychiatric disorder: A preliminary study. Frontiers in Cellular and Infection Microbiology, 13, 1124846. https://doi.org/10.3389/fcimb.2023.1124846
Kamath, S., Stringer, A. M., Prestidge, C. A., & Joyce, P. (2023). Targeting the gut microbiome to control drug pharmacomicrobiomics: The next frontier in oral drug delivery. Expert Opinion on Drug Delivery, 1–17, 1315–1331. https://doi.org/10.1080/17425247.2023.2233900
Kao, A. C. C., Harty, S., & Burnet, P. W. J. (2016). The Influence of Prebiotics on Neurobiology and Behavior. In International review of neurobiology (Vol. 131) (pp. 21–48). Elsevier. https://doi.org/10.1016/bs.irn.2016.08.007
Kao, A. C.‐C., Burnet, P. W. J., & Lennox, B. R. (2018). Can prebiotics assist in the management of cognition and weight gain in schizophrenia? Psychoneuroendocrinology, 95, 179–185. https://doi.org/10.1016/j.psyneuen.2018.05.027
Kao, A. C.‐C., Spitzer, S., Anthony, D. C., Lennox, B., & Burnet, P. W. J. (2018). Prebiotic attenuation of olanzapine‐induced weight gain in rats: Analysis of central and peripheral biomarkers and gut microbiota. Translational Psychiatry, 8(1), 66. https://doi.org/10.1038/s41398-018-0116-8
Kishi, T., Yoshimura, R., Sakuma, K., Okuya, M., & Iwata, N. (2020). Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan. Neuropsychopharmacology Reports, 40(4), 417–422. https://doi.org/10.1002/npr2.12137
Koliada, A., Syzenko, G., Moseiko, V., Budovska, L., Puchkov, K., Perederiy, V., Gavalko, Y., Dorofeyev, A., Romanenko, M., Tkach, S., Sineok, L., Lushchak, O., & Vaiserman, A. (2017). Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiology, 17(1), 120. https://doi.org/10.1186/s12866-017-1027-1
Letertre, M. P. M., Munjoma, N., Wolfer, K., Pechlivanis, A., McDonald, J. A. K., Hardwick, R. N., Cherrington, N. J., Coen, M., Nicholson, J. K., Hoyles, L., Swann, J. R., & Wilson, I. D. (2020). A two‐way interaction between methotrexate and the gut microbiota of male Sprague‐Dawley rats. Journal of Proteome Research, 19(8), 3326–3339. https://doi.org/10.1021/acs.jproteome.0c00230
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple‐treatments meta‐analysis. The Lancet, 382(9896), 951–962. https://doi.org/10.1016/S0140-6736(13)60733-3
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P. H., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., & Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of pharmacology: Updated guidance for 2020. British Journal of Pharmacology, 177(16), 3611–3616. https://doi.org/10.1111/bph.15178
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. (2014). Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double‐blind, placebo‐controlled study. American Journal of Psychiatry, 171(2), 160–168. https://doi.org/10.1176/appi.ajp.2013.13070984
Magne, F., Gotteland, M., Gauthier, L., Zazueta, A., Pesoa, S., Navarrete, P., & Balamurugan, R. (2020). The Firmicutes/Bacteroidetes ratio: A relevant marker of gut Dysbiosis in obese patients? Nutrients, 12(5), 1474. https://doi.org/10.3390/nu12051474
Mann, S., Chintoh, A., Giacca, A., Fletcher, P., Nobrega, J., Hahn, M., & Remington, G. (2013). Chronic olanzapine administration in rats: Effect of route of administration on weight, food intake and body composition. Pharmacology Biochemistry and Behavior, 103(4), 717–722. https://doi.org/10.1016/j.pbb.2012.12.002
Mazereel, V., Detraux, J., Vancampfort, D., Van Winkel, R., & De Hert, M. (2020). Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness. Frontiers in Endocrinology, 11, 573479. https://doi.org/10.3389/fendo.2020.573479
Meyer, J. M., Mao, Y., Pikalov, A., Cucchiaro, J., & Loebel, A. (2015). Weight change during long‐term treatment with lurasidone: Pooled analysis of studies in patients with schizophrenia. International Clinical Psychopharmacology, 30(6), 342–350. https://doi.org/10.1097/YIC.0000000000000091
Meyer, J. M., Ng‐Mak, D. S., Chuang, C.‐C., Rajagopalan, K., & Loebel, A. (2017). Weight changes before and after lurasidone treatment: A real‐world analysis using electronic health records. Annals of General Psychiatry, 16(1), 36. https://doi.org/10.1186/s12991-017-0159-x
Minichino, A., Preston, T., Fanshawe, J. B., Fusar‐Poli, P., McGuire, P., Burnet, P. W. J., & Lennox, B. R. (2023). Psycho‐pharmacomicrobiomics: A systematic review and meta‐analysis. Biological Psychiatry, 95(7), 611–628. https://doi.org/10.1016/j.biopsych.2023.07.019
Moreau, N., Goupry, S., Antignac, J., Monteau, F., Lebizec, B., Champ, M., Martin, L., & Dumon, H. (2003). Simultaneous measurement of plasma concentrations and 13C‐enrichment of short‐chain fatty acids, lactic acid and ketone bodies by gas chromatography coupled to mass spectrometry. Journal of Chromatography B, 784(2), 395–403. https://doi.org/10.1016/S1570-0232(02)00827-9
Morgan, A. P., Crowley, J. J., Nonneman, R. J., Quackenbush, C. R., Miller, C. N., Ryan, A. K., Bogue, M. A., Paredes, S. H., Yourstone, S., Carroll, I. M., Kawula, T. H., Bower, M. A., Sartor, R. B., & Sullivan, P. F. (2014). The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS ONE, 9(12), e115225. https://doi.org/10.1371/journal.pone.0115225
Munawar, N., Ahsan, K., Muhammad, K., Ahmad, A., Anwar, M. A., Shah, I., Al Ameri, A. K., & Al Mughairbi, F. (2021). Hidden role of gut microbiome Dysbiosis in schizophrenia: Antipsychotics or Psychobiotics as therapeutics? International Journal of Molecular Sciences, 22(14), 7671. https://doi.org/10.3390/ijms22147671
Nemeroff, C. B. (1997). Dosing the antipsychotic medication olanzapine. The Journal of Clinical Psychiatry, 58(Suppl 10), 45–49.
Ng‐Mak, D., Tongbram, V., Ndirangu, K., Rajagopalan, K., & Loebel, A. (2018). Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: A network meta‐analysis. Journal of Comparative Effectiveness Research, 7(8), 737–748. https://doi.org/10.2217/cer-2018-0016
Nguyen, T. T., Kosciolek, T., Maldonado, Y., Daly, R. E., Martin, A. S., McDonald, D., Knight, R., & Jeste, D. V. (2019). Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects. Schizophrenia Research, 204, 23–29. https://doi.org/10.1016/j.schres.2018.09.014
Palmnäs‐Bédard, M. S., Costabile, G., Vetrani, C., Åberg, S., Hjalmarsson, Y., Dicksved, J., Riccardi, G., & Landberg, R. (2022). The human gut microbiota and glucose metabolism: A scoping review of key bacteria and the potential role of SCFAs. The American Journal of Clinical Nutrition, 116(4), 862–874. https://doi.org/10.1093/ajcn/nqac217
Park, S., Yi, K. K., Kim, M.‐S., & Hong, J. P. (2013). Effects of ziprasidone and olanzapine on body composition and metabolic parameters: An open‐label comparative pilot study. Behavioral and Brain Functions, 9(1), 27. https://doi.org/10.1186/1744-9081-9-27
Percie Du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410
Pochiero, I., Calisti, F., Comandini, A., Del Vecchio, A., Costamagna, I., Rosignoli, M. T., Cattaneo, A., Nunna, S., Peduto, I., Heiman, F., Chang, H.‐C., Chen, C.‐C., & Correll, C. (2021). Impact of Lurasidone and other antipsychotics on body weight: Real‐world, retrospective, comparative study of 15,323 adults with schizophrenia. International Journal of General Medicine, 14, 4081–4094. https://doi.org/10.2147/IJGM.S320611
Qian, L., He, X., Liu, Y., Gao, F., Lu, W., Fan, Y., Gao, Y., Wang, W., Zhu, F., Wang, Y., & Ma, X. (2023). Longitudinal gut microbiota dysbiosis underlies olanzapine‐induced weight gain. Microbiology Spectrum, 11(4), e0005823. https://doi.org/10.1128/spectrum.00058-23
Radford‐Smith, D. E., & Anthony, D. C. (2023). Prebiotic and probiotic modulation of the microbiota–gut–brain Axis in depression. Nutrients, 15(8), 1880. https://doi.org/10.3390/nu15081880
Radford‐Smith, D. E., Probert, F., Burnet, P. W. J., & Anthony, D. C. (2022). Modifying the maternal microbiota alters the gut–brain metabolome and prevents emotional dysfunction in the adult offspring of obese dams. Proceedings of the National Academy of Sciences, 119(9), e2108581119. https://doi.org/10.1073/pnas.2108581119
Ratzoni, G., Gothelf, D., Brand‐Gothelf, A., Reidman, J., Kikinzon, L., Gal, G., Phillip, M., Apter, A., & Weizman, R. (2002). Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. Journal of the American Academy of Child & Adolescent Psychiatry, 41(3), 337–343. https://doi.org/10.1097/00004583-200203000-00014
Reynolds, G. P., Dalton, C. F., Watrimez, W., Jackson, J., & Harte, M. K. (2019). Adjunctive Lurasidone suppresses food intake and weight gain associated with olanzapine Administration in Rats. Clinical Psychopharmacology and Neuroscience, 17(2), 314–317. https://doi.org/10.9758/cpn.2019.17.2.314
Ruder, B., Atreya, R., & Becker, C. (2019). Tumour necrosis factor alpha in intestinal homeostasis and gut related diseases. International Journal of Molecular Sciences, 20(8), 1887. https://doi.org/10.3390/ijms20081887
Safadi, J. M., Quinton, A. M. G., Lennox, B. R., Burnet, P. W. J., & Minichino, A. (2022). Gut dysbiosis in severe mental illness and chronic fatigue: A novel trans‐diagnostic construct? A systematic review and meta‐analysis. Molecular Psychiatry, 27(1), 141–153. https://doi.org/10.1038/s41380-021-01032-1
Sarkar, A., Harty, S., Johnson, K. V. ‐A., Moeller, A. H., Carmody, R. N., Lehto, S. M., Erdman, S. E., Dunbar, R. I. M., & Burnet, P. W. J. (2020). The role of the microbiome in the neurobiology of social behaviour. Biological Reviews, 95(5), 1131–1166. https://doi.org/10.1111/brv.12603
Sarkar, A., Lehto, S. M., Harty, S., Dinan, T. G., Cryan, J. F., & Burnet, P. W. J. (2016). Psychobiotics and the manipulation of bacteria‐gut‐brain signals. Trends in Neurosciences, 39(11), 763–781. https://doi.org/10.1016/j.tins.2016.09.002
Seeman, M. V. (2021). The gut microbiome and antipsychotic treatment response. Behavioural Brain Research, 396, 112886. https://doi.org/10.1016/j.bbr.2020.112886
Spitzer, S. O., Tkacz, A., Savignac, H. M., Cooper, M., Giallourou, N., Mann, E. O., Bannerman, D. M., Swann, J. R., Anthony, D. C., Poole, P. S., & Burnet, P. W. J. (2021). Postnatal prebiotic supplementation in rats affects adult anxious behaviour, hippocampus, electrophysiology, metabolomics, and gut microbiota. iScience, 24(10), 103113. https://doi.org/10.1016/j.isci.2021.103113
Subramaniam, S., Elz, A., Wignall, A., Kamath, S., Ariaee, A., Hunter, A., Newblack, T., Wardill, H. R., Prestidge, C. A., & Joyce, P. (2023). Self‐emulsifying drug delivery systems (SEDDS) disrupt the gut microbiota and trigger an intestinal inflammatory response in rats. International Journal of Pharmaceutics, 648, 123614. https://doi.org/10.1016/j.ijpharm.2023.123614
Subramaniam, S., Kamath, S., Ariaee, A., Prestidge, C., & Joyce, P. (2023). The impact of common pharmaceutical excipients on the gut microbiota. Expert Opinion on Drug Delivery, 1–18, 1297–1314. https://doi.org/10.1080/17425247.2023.2223937
Tomizawa, Y., Kurokawa, S., Ishii, D., Miyaho, K., Ishii, C., Sanada, K., Fukuda, S., Mimura, M., & Kishimoto, T. (2021). Effects of Psychotropics on the microbiome in patients with depression and anxiety: Considerations in a naturalistic clinical setting. International Journal of Neuropsychopharmacology, 24(2), 97–107. https://doi.org/10.1093/ijnp/pyaa070
Tuson, H. H., Foley, M. H., Koropatkin, N. M., & Biteen, J. S. (2018). The starch utilization system assembles around stationary starch‐binding proteins. Biophysical Journal, 115(2), 242–250. https://doi.org/10.1016/j.bpj.2017.12.015
Vacca, M., Celano, G., Calabrese, F. M., Portincasa, P., Gobbetti, M., & De Angelis, M. (2020). The controversial role of human gut Lachnospiraceae. Microorganisms, 8(4), 573. https://doi.org/10.3390/microorganisms8040573
Wos‐Oxley, M. L., Bleich, A., Oxley, A. P. A., Kahl, S., Janus, L. M., Smoczek, A., Nahrstedt, H., Pils, M. C., Taudien, S., Platzer, M., Hedrich, H.‐J., Medina, E., & Pieper, D. H. (2012). Comparative evaluation of establishing a human gut microbial community within rodent models. Gut Microbes, 3(3), 234–249. https://doi.org/10.4161/gmic.19934
Zafar, H., & Saier, M. H. (2021). Gut Bacteroides species in health and disease. Gut Microbes, 13(1), 1848158–20. https://doi.org/10.1080/19490976.2020.1848158